The use of antibody fragments has emerged as a promising approach to target both Aβ and tau pathology in Alzheimer’s disease [32–34, 39, 40, 42–45, 85]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.